A detailed history of Comgest Global Investors S.A.S. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Comgest Global Investors S.A.S. holds 152,777 shares of BMRN stock, worth $10.2 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares
152,777
Previous 212,464 28.09%
Holding current value
$10.2 Million
Previous $18.6 Million 32.22%
% of portfolio
0.2%
Previous 0.3%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

SELL
$74.43 - $92.22 $4.44 Million - $5.5 Million
-59,687 Reduced 28.09%
152,777 $12.6 Million
Q1 2024

May 07, 2024

BUY
$83.81 - $99.0 $1.1 Million - $1.3 Million
13,143 Added 6.59%
212,464 $18.6 Million
Q4 2023

Feb 12, 2024

BUY
$76.22 - $98.51 $1.7 Million - $2.2 Million
22,313 Added 12.61%
199,321 $19.2 Million
Q3 2023

Nov 07, 2023

BUY
$85.07 - $94.48 $2.84 Million - $3.16 Million
33,401 Added 23.26%
177,008 $15.7 Million
Q2 2023

Jul 24, 2023

BUY
$86.68 - $100.3 $1.93 Million - $2.23 Million
22,273 Added 18.36%
143,607 $12.4 Million
Q1 2023

May 15, 2023

SELL
$87.74 - $117.27 $1.37 Million - $1.83 Million
-15,574 Reduced 11.38%
121,334 $11.8 Million
Q4 2022

May 15, 2023

BUY
$80.93 - $108.63 $849,198 - $1.14 Million
10,493 Added 8.3%
136,908 $14.2 Million
Q4 2022

Feb 10, 2023

BUY
$80.93 - $108.63 $849,198 - $1.14 Million
10,493 Added 8.3%
136,908 $14.2 Million
Q3 2022

May 15, 2023

BUY
$82.16 - $96.94 $542,256 - $639,804
6,600 Added 5.51%
126,415 $10.7 Million
Q3 2022

Nov 10, 2022

BUY
$82.16 - $96.94 $542,256 - $639,804
6,600 Added 5.51%
126,415 $10.7 Million
Q2 2022

May 15, 2023

BUY
$71.48 - $86.85 $943,750 - $1.15 Million
13,203 Added 12.38%
119,815 $9.93 Million
Q2 2022

Jul 28, 2022

BUY
$71.48 - $86.85 $943,750 - $1.15 Million
13,203 Added 12.38%
119,815 $9.93 Million
Q1 2022

May 15, 2023

SELL
$74.28 - $92.69 $1.09 Million - $1.36 Million
-14,722 Reduced 12.13%
106,612 $8.22 Million
Q1 2022

May 13, 2022

BUY
$74.28 - $92.69 $164,753 - $205,586
2,218 Added 2.12%
106,612 $8.22 Million
Q4 2021

Feb 14, 2022

SELL
$71.72 - $91.47 $197,301 - $251,633
-2,751 Reduced 2.57%
104,394 $9.22 Million
Q3 2021

Nov 02, 2021

BUY
$74.77 - $85.47 $1.16 Million - $1.33 Million
15,529 Added 16.95%
107,145 $8.28 Million
Q2 2021

Aug 12, 2021

BUY
$75.51 - $84.79 $105,714 - $118,706
1,400 Added 1.55%
91,616 $7.64 Million
Q1 2021

May 14, 2021

SELL
$74.73 - $90.69 $298,920 - $362,760
-4,000 Reduced 4.25%
90,216 $6.81 Million
Q4 2020

Feb 16, 2021

SELL
$72.61 - $90.2 $72,610 - $90,200
-1,000 Reduced 1.05%
94,216 $8.26 Million
Q3 2020

Nov 13, 2020

BUY
$71.87 - $131.03 $970,245 - $1.77 Million
13,500 Added 16.52%
95,216 $7.24 Million
Q2 2020

Jul 31, 2020

SELL
$79.55 - $124.22 $175,010 - $273,284
-2,200 Reduced 2.62%
81,716 $10.1 Million
Q1 2020

May 07, 2020

SELL
$71.37 - $96.85 $241,087 - $327,159
-3,378 Reduced 3.87%
83,916 $7.09 Million
Q4 2019

Feb 13, 2020

BUY
$64.27 - $86.37 $1.05 Million - $1.41 Million
16,294 Added 22.95%
87,294 $7.38 Million
Q3 2019

Nov 05, 2019

BUY
$67.4 - $85.11 $889,680 - $1.12 Million
13,200 Added 22.84%
71,000 $4.79 Million
Q2 2019

Aug 08, 2019

BUY
$80.35 - $93.9 $289,260 - $338,040
3,600 Added 6.64%
57,800 $4.95 Million
Q1 2019

May 09, 2019

BUY
$84.2 - $98.62 $1.01 Million - $1.18 Million
12,000 Added 28.44%
54,200 $4.81 Million
Q4 2018

Feb 12, 2019

BUY
$80.14 - $106.07 $609,064 - $806,132
7,600 Added 21.97%
42,200 $3.59 Million
Q3 2018

Nov 06, 2018

BUY
$93.92 - $105.72 $432,032 - $486,312
4,600 Added 15.33%
34,600 $3.36 Million
Q4 2017

Feb 09, 2018

BUY
$80.76 - $95.13 $363,420 - $428,085
4,500 Added 17.65%
30,000 $2.68 Million
Q3 2017

Nov 07, 2017

BUY
$80.6 - $94.95 $120,899 - $142,425
1,500 Added 6.25%
25,500 $2.37 Million
Q2 2017

Aug 09, 2017

BUY
N/A
24,000
24,000 $2.18 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.4B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Comgest Global Investors S.A.S. Portfolio

Follow Comgest Global Investors S.A.S. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Comgest Global Investors S.A.S., based on Form 13F filings with the SEC.

News

Stay updated on Comgest Global Investors S.A.S. with notifications on news.